Skip to main content

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

New Online Registration Required for Live Call to Ask Questions

Audio-Only Webcast Still Available on Concert’s Website

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update.

Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.78
+7.83 (3.90%)
AAPL  253.50
+6.87 (2.79%)
AMD  202.59
+6.55 (3.34%)
BAC  48.55
+1.33 (2.81%)
GOOG  286.03
+12.89 (4.72%)
META  571.13
+34.75 (6.48%)
MSFT  370.22
+11.26 (3.14%)
NVDA  173.49
+8.32 (5.03%)
ORCL  146.63
+7.83 (5.64%)
TSLA  372.25
+16.97 (4.78%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.